Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NUP205 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NUP205 siRNA is a small interfering RNA designed to silence the expression of the NUP205 gene, which encodes a 205 kDa component of the nuclear pore complex (NPC). In the context of liver hepatocellular carcinoma (LIHC), NUP205 is frequently overexpressed and is associated with advanced clinicopathological features, poor prognosis, and resistance to chemotherapeutic agents like doxorubicin. By utilizing the RNA interference (RNAi) pathway, this siRNA targets NUP205 mRNA for degradation, leading to a significant reduction in NUP205 protein levels. Experimental studies have shown that NUP205 knockdown inhibits tumor cell proliferation and migration, and restores sensitivity to chemotherapy. It is currently utilized as a research tool to validate NUP205 as a potential therapeutic target and prognostic biomarker in oncology.
- Other names
- siNUP205siNUP-205siNUP 205small interfering RNA targeting NUP205
02
Targets
NUP205 (Nuclear pore complex protein Nup205)
Beyond the preview
Go deeper on NUP205 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NUP205 siRNA.